These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 24342015)

  • 1. [New drugs in the treatment of multiple myeloma].
    Oriol A; Motlló C
    Med Clin (Barc); 2014 Sep; 143(6):268-74. PubMed ID: 24342015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel therapies for relapsed myeloma.
    Stewart AK
    Hematology Am Soc Hematol Educ Program; 2009; ():578-86. PubMed ID: 20008242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging therapies in multiple myeloma.
    El-Amm J; Tabbara IA
    Am J Clin Oncol; 2015 Jun; 38(3):315-21. PubMed ID: 23934133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma.
    Pantani L; Brioli A; Tacchetti P; Zannetti BA; Mancuso K; Rocchi S; Martello M; Rizzello I; Terragna C; Zamagni E; Cavo M
    Expert Rev Hematol; 2016 Mar; 9(3):315-23. PubMed ID: 26634945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease.
    Ashjian E; Redic K
    J Oncol Pharm Pract; 2016 Apr; 22(2):289-302. PubMed ID: 25694345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel therapies in monoclonal gammopathies.
    Niesvizky R
    Hematology; 2012 Apr; 17 Suppl 1():S121-4. PubMed ID: 22507798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigational treatments for multiple myeloma.
    Bringhen S; Avonto I; Magarotto V; Boccadoro M; Palumbo A
    Expert Opin Investig Drugs; 2006 Dec; 15(12):1565-82. PubMed ID: 17107282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Molecular targeting therapy for multiple myeloma].
    Takatoku M
    Nihon Rinsho; 2007 Dec; 65(12):2345-50. PubMed ID: 18069281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Molecular targeting agents for multiple myeloma].
    Fujii S; Abe M
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():518-23. PubMed ID: 23513894
    [No Abstract]   [Full Text] [Related]  

  • 10. [Current status of clinical trials of novel agents for multiple myeloma].
    Kuroda J
    Rinsho Ketsueki; 2014 Oct; 55(10):2005-15. PubMed ID: 25297766
    [No Abstract]   [Full Text] [Related]  

  • 11. Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma.
    Jagannath S; Dimopoulos MA; Lonial S
    Leuk Res; 2010 Sep; 34(9):1111-8. PubMed ID: 20472288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pomalidomide: when expectations are understated.
    Di Raimondo F; Conticello C
    Future Oncol; 2017 Feb; 13(5s):1-2. PubMed ID: 28116940
    [No Abstract]   [Full Text] [Related]  

  • 13. Novel targeted agents in the treatment of multiple myeloma.
    Varga C; Laubach J; Hideshima T; Chauhan D; Anderson KC; Richardson PG
    Hematol Oncol Clin North Am; 2014 Oct; 28(5):903-25. PubMed ID: 25212889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pomalidomide for multiple myeloma.
    Fouquet G; Bories C; Guidez S; Renaud L; Herbaux C; Javed S; Facon T; Leleu X
    Expert Rev Hematol; 2014 Dec; 7(6):719-31. PubMed ID: 25265911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel therapeutics in multiple myeloma.
    Stewart AK
    Hematology; 2012 Apr; 17 Suppl 1(0 1):S105-8. PubMed ID: 22507794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding novel therapeutic agents for multiple myeloma.
    Tariman JD
    Clin J Oncol Nurs; 2003; 7(5):521-8. PubMed ID: 14603548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Future directions in immunomodulatory therapy.
    Lonial S
    Med Oncol; 2010 Jun; 27 Suppl 1():S62-6. PubMed ID: 20012563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel agents in development for peripheral T-cell lymphoma.
    O'Connor OA
    Semin Hematol; 2010 Apr; 47 Suppl 1():S11-4. PubMed ID: 20359580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies.
    Morgan G
    Blood Rev; 2010 Nov; 24 Suppl 1():S27-32. PubMed ID: 21126634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma.
    Palumbo A; Sonneveld P
    Expert Rev Hematol; 2015 Aug; 8(4):481-91. PubMed ID: 26070331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.